[go: up one dir, main page]

AR100820A1 - FORMULATIONS OF COMPRESSED BI-LAYER OF CYCLOFOSPHAMIDE AND CAPECITABINE AND HIGHLY FRACTIONED METRONOMIC ADMINISTRATION OF THE SAME - Google Patents

FORMULATIONS OF COMPRESSED BI-LAYER OF CYCLOFOSPHAMIDE AND CAPECITABINE AND HIGHLY FRACTIONED METRONOMIC ADMINISTRATION OF THE SAME

Info

Publication number
AR100820A1
AR100820A1 ARP150101871A ARP150101871A AR100820A1 AR 100820 A1 AR100820 A1 AR 100820A1 AR P150101871 A ARP150101871 A AR P150101871A AR P150101871 A ARP150101871 A AR P150101871A AR 100820 A1 AR100820 A1 AR 100820A1
Authority
AR
Argentina
Prior art keywords
formulations
layer
capecitabine
cyclofosphamide
fractioned
Prior art date
Application number
ARP150101871A
Other languages
Spanish (es)
Original Assignee
Sanofi-Synthelabo (India) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo (India) Ltd filed Critical Sanofi-Synthelabo (India) Ltd
Publication of AR100820A1 publication Critical patent/AR100820A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulación de comprimido oral bi-capa de ciclofosfamida y capecitabina y métodos de preparación de estas formulaciones. Además, dichas formulaciones son útiles para administración metronómica para tratar cáncer, por ejemplo, cáncer de mama. Reivindicación 4: La formulación de comprimido de una cualquiera de las reivindicaciones 1 a 3, en la que el único comprimido bi-capa está recubierto con película. Reivindicación 7: La formulación de comprimido de la reivindicación 6, en la que el recubrimiento con película aplicado comprende la composición siguiente: @@@@@@@@@Formulation of oral tablet bi-layer of cyclophosphamide and capecitabine and methods of preparation of these formulations. In addition, such formulations are useful for metronomic administration to treat cancer, for example, breast cancer. Claim 4: The tablet formulation of any one of claims 1 to 3, wherein the single bi-layer tablet is film coated. Claim 7: The tablet formulation of claim 6, wherein the applied film coating comprises the following composition: @@@@@@@@@@

ARP150101871A 2014-06-12 2015-06-11 FORMULATIONS OF COMPRESSED BI-LAYER OF CYCLOFOSPHAMIDE AND CAPECITABINE AND HIGHLY FRACTIONED METRONOMIC ADMINISTRATION OF THE SAME AR100820A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1596DE2014 2014-06-12

Publications (1)

Publication Number Publication Date
AR100820A1 true AR100820A1 (en) 2016-11-02

Family

ID=53724388

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101871A AR100820A1 (en) 2014-06-12 2015-06-11 FORMULATIONS OF COMPRESSED BI-LAYER OF CYCLOFOSPHAMIDE AND CAPECITABINE AND HIGHLY FRACTIONED METRONOMIC ADMINISTRATION OF THE SAME

Country Status (3)

Country Link
AR (1) AR100820A1 (en)
TW (1) TW201613563A (en)
WO (1) WO2015189807A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018013428A (en) * 2016-05-03 2019-10-07 Intas Pharmaceuticals Ltd Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539769A (en) * 2006-06-02 2009-11-19 アリアド ジーン セラピューティクス インコーポレイテッド Capecitabine combination therapy
EP2747571A4 (en) * 2011-08-24 2015-05-27 David Kerr Low-dose combination chemotherapy
AU2014326142B2 (en) * 2013-09-30 2019-07-25 Intas Pharmaceuticals Limited Pharmaceutical composition comprising capecitabine and cyclophosphamide

Also Published As

Publication number Publication date
TW201613563A (en) 2016-04-16
WO2015189807A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
DOP2019000005A (en) 3-METIL PIRAZINAS 2,5-DISUSTITUIDAS AND 3-METIL PIRAZINAS 2,5,6-TRISUSTITUIDAS AS ALLOSTERIC INHIBITORS OF SHP2
MX2024012899A (en) CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR THE TREATMENT OF BETA HEMOGLOBINOPATHIES
CO2017001994A2 (en) Active compounds towards bromodomains
MX2020011104A (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE.
CO2018008207A2 (en) Compositions for oral care and methods for using the compositions
CL2018001686A1 (en) Methods and compositions particularly for the treatment of attention deficit disorder (divisional application 201701026)
MX2019010322A (en) Pharmaceutical compositions for combination therapy.
CR20180228A (en) ATTACHED THERAPY WITH 25-HYDROXY VITAMIN D AND ARTICLES THEREOF
ECSP17053843A (en) POWDERED NASAL FORMULATION FOR THE TREATMENT OF HYPOGLYCEMIA
CL2016002560A1 (en) Oral solid pharmaceutical dosage form comprising siponimod, a moisture protective agent and optionally a pharmaceutical excipient; Preparation procedure
CO2019008103A2 (en) Pharmaceutical compositions for combination therapy
MX2023001963A (en) HYPERTONIC PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTIPLATIN CHEMOPPROTECTIVE AGENT.
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
MX387731B (en) ORAL PHARMACEUTICAL COMPOSITIONS OF MESALAZINE.
CR20150653A (en) NEW COMPOUNDS FOR CANCER TREATMENT
CL2018001590A1 (en) Pharmaceutical compositions comprising some phenylaminopyrimidine derivative.
UY37729A (en) NEW COMPOUNDS THAT INHIBIT THE ACTIVITY OF Nav1.7
PH12016502386B1 (en) Oral care compositions
CL2019003288A1 (en) A pharmaceutical combination for the treatment of cancer.
BR112018071363A2 (en) oral nicotinamide pharmaceutical compositions
AR100820A1 (en) FORMULATIONS OF COMPRESSED BI-LAYER OF CYCLOFOSPHAMIDE AND CAPECITABINE AND HIGHLY FRACTIONED METRONOMIC ADMINISTRATION OF THE SAME
MX2017004909A (en) Tryptamide compositions and methods of use.
BR112017012938A2 (en) oral use of a composition and method to enhance the appearance of cellulite
BR112019017314A2 (en) pharmaceutical compositions for combination therapy
MX2019015869A (en) NEW ORAL FORMULATIONS OF BELINOSTAT.

Legal Events

Date Code Title Description
FB Suspension of granting procedure